Applications of PET imaging of neurological tumors with radiolabeled amino acids

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 59, Issue 1, 2015, Pages 70-82

  Galldiks, N ^a,b   Langen, K J ^b,c,d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

^c Juelich Aachen Research Alliance JARA Section JARA Brain   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Amino acids; Brain neoplasms; Positron emission tomography

Indexed keywords

3,4 DIHYDROXY 6 FLUOROPHENYLALANINE F 18; AMINO ACID; BEVACIZUMAB; FLUOROETHYLTYROSINE F 18; METHYLMETHIONINE C 11; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG; FLUORINE;

ARTICLE; BRAIN METASTASIS; BRAIN TUMOR; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CLINICAL DECISION MAKING; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG UPTAKE; EARLY DIAGNOSIS; GLIOBLASTOMA; GLIOMA; HUMAN; ISOTOPE LABELING; NEUROSURGERY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR RECURRENCE; ANIMAL; BRAIN NEOPLASMS; DIAGNOSTIC USE; IMAGE ENHANCEMENT; MOLECULAR IMAGING; PROCEDURES;

AMINO ACIDS; ANIMALS; BRAIN NEOPLASMS; FLUORINE RADIOISOTOPES; HUMANS; IMAGE ENHANCEMENT; ISOTOPE LABELING; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84944723853     PISSN: 18244785     EISSN: 18271936     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Van Den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol 2009;27:2905-8.
2. Herholz K, Langen KJ, Schlepers C, Mountz JM. Brain tumors. Semin Nucl Med 2012;42:356-70.
3. Wester HJ, Herz M, Weber W, Heiss P, Senekowitsch-Schmidtke R, Schwaiger M et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 1999;40:205-12.
4. Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D et al. O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 2006;33:287-94.
5. Becherer A, Karanikas G, Szabo M, Zettinig G, Asenbaum S, Marosi C et al. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging. 2003;30:1561-7.
6. Juhasz C, Dwivedi S, Kamson DO, Michelhaugh SK, Mittal S. Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors. Mol Imaging. 2014;13.
7. McConathy J, Goodman MM. Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography. Cancer metastasis reviews. 2008;27:555-73.
8. Ishiwata K, Kubota K, Murakami M, Kubota R, Sasaki T, Ishii S et al. Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med 1993;34:1936-43.
9. Wienhard K, Herholz K, Coenen HH, Rudolf J, Kling P, Stöcklin G et al. Increased amino acid transport into brain tumors measured by PET of L-(2-18F) fluorotyrosine. J Nucl Med 1991;32:1338-46.
10. Youland RS, Kitange GJ, Peterson TE, Pafundi DH, Ramiscal JA, Pokorny JL et al. The role of LAT1 in (18) F-DOPA uptake in malignant gliomas. J Neurooncol 2013;111:11-8.
11. Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F et al. An interindividual comparison of O-(2-[(18) F] Fluoroethyl)-L-Tyrosine (FET) - and L-[Methyl-(11) C]Methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys 2011;81:1049-58.
12. Langen KJ, Jarosch M, Mühlensiepen H, Hamacher K, Broer S, Jansen P et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol 2003;30:501-8.
13. Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C] methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000;27:542-9.
14. Kratochwil C, Combs SE, Leotta K, Afshar-Oromieh A, Rieken S, Debus J et al. Intra-individual comparison of (18) F-FET and (18) F-DOPA in PET imaging of recurrent brain tumors. Neuro Oncol 2014;16:434-40.
15. Lapa C, Linsenmann T, Monoranu CM, Samnick S, Buck AK, Bluemel C et al. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients. J Nucl Med 2014;55:1611-6.
16. Floeth FW, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider MJ et al. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 2007;48:519-27.
17. Rapp M, Floeth FW, Felsberg J, Steiger HJ, Sabel M, Langen KJ et al. Clinical value of O-(2-[(18) F]-fluoroefhyl)-L-tyrosine positron emission tomography in patients with low-grade glioma. Neurosurg Focus 2013;34:E3.
18. Singhai T, Narayanan TK, Jain V, Mukherjee J, Mantil J. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 2008;10:1-18.
19. Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M et al. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol 2013;15:341-51.
20. Pichler R, Dunzinger A, Wurm G, Pichler J, Weis S, Nussbaumer K et al. Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? Eur J Nucl Med Mol Imaging 2010;37:1521-8.
21. Vander Borght T, Asenbaum S, Bartenstein P, Halldin C, Kapucu O, Van Laere K et al. EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging 2006;33:1374-80.
22. Floeth FW, Pauleit D, Sabel M, Reifenberger G, Stoffels G, Stummer W et al. 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med 2006;47:776-82.
23. Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, Van Rheenen RW, Walenkamp AM et al. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging 2013;40:615-35.
24. Dunet V, Rossier C, Buck A, Stupp R, Prior JO. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and metaanalysis. J Nucl Med 2012;53:207-14.
25. Rapp M, Heinzel A, Galldiks N, Stoffels G, Felsberg J, Ewelt C et al. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med 2013;54:229-35.
26. Ceyssens S, Van Laere K, De Groot T, Goffin J, Bormans G, Mortelmans L. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol 2006;27:1432-7.
27. Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Müller HW et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005;128:678-87.
28. Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S et al. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 2012;39:1021-9.
29. Popped G, Krefh FW, Mehrkens JH, Herms J, Seelos K, Koch W et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 2007;34:1933-42.
30. Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI et al. 11C-methionine PET for differential diagnosis of lowgrade gliomas. Neurology 1998;50:1316-22.
31. Stockhammer F, Plotkin M, Amthauer H, Van Landeghem FK, Woiciechowsky C. Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas. J Neurooncol 2008;88:205-10.
32. Wyss MT, Hofer S, Hefti M, Bartschi E, Uhlmann C, Treyer V et al. Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake. J Nucl Med 2007;48:1047-52.
33. Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A et al. Methyl-[11C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 2003;30:868-73.
34. Weckesser M, Langen KJ, Rickert CH, Kloska S, Straeter R, Hamacher K et al. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 2005;32:422-9.
35. Moulin-Romsee G, D'Hondt E, De Groot T, Goffin J, Sciot R, Mortelmans L et al. Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine? Eur J Nucl Med Mol Imaging 2007;34:2082-7.
36. Calcagni ML, Galli G, Giordano A, Taralli S, Anile C, Niesen A et al. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Clin Nucl Med 2011;36:841-7.
37. Jansen NL, Suchorska B, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A et al. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med 2014;55:198-203.
38. Kunz M, Thon N, Eigenbrod S, Hartmann C, Egensperger R, Herms J et al. Hot spots in dynamic (18) FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro Oncol 2011;13:307-16.
39. Pöpped G, Krefh FW, Herms J, Koch W, Mehrkens JH, Gildehaus FJ et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med 2006;47:393-403.
40. Galldiks N, Stoffels G, Ruge MI, Rapp M, Sabel M, Reifenberger G et al. Role of O-(2-18F-Fluoroethyl)-L-Tyrosine PET as a Diagnostic Tool for Detection of Malignant Progression in Patients with Low-Grade Glioma. J Nucl Med 2013;54:2046-54.
41. Singhai T, Narayanan TK, Jacobs MP, Bal C, Mantil JC. C-11-Methionine PET for Grading and Prognostication in Gliomas: A Comparison Study with F-18-FDG PET and Contrast Enhancement on MRI. J Nucl Med 2012;53:1709-15.
42. Karunanithi S, Sharma P, Kumar A, Gupta DK, Khangembam BC, Ballal S et al. Can (18) F-FDOPA PET/CT predict survival in patients with suspected recurrent glioma? A prospective study. Eur J Radiol 2014;83:219-25.
43. Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Langstrom B et al. Positron emission tomography (11) C-methionine and survival in patients with low-grade gliomas. Cancer 2001;92:1541-9.
44. Smits A, Baumert BG. The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II. Int J Mol Imaging 2011;2011:372509.
45. Smits A, Westerberg E, Ribom D. Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas. Eur J Nucl Med Mol Imaging 2008;35:65-71.
46. Galldiks N, Dunkl V, Kracht LW, Vollmar S, Jacobs AH, Fink GR et al. Volumetry of [(1) (1) C]-methionine positron emission tomographic uptake as a prognostic marker before treatment of patients with malignant glioma. Molecular Imaging 2012;11:516-27.
47. Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 2004;10:7163-70.
48. Mosskin M, Ericson K, Hindmarsh T, Von Holst H, Collins VP, Bergstrom M et al. Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol 1989;30:225-32.
49. Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C et al. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol 2013 [Epub ahead of print].
50. Pirotte B, Goldman S, Massager N, David P, Wikler D, Lipszyc M et al. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. Journal of Neurosurgery 2004;101:476-83.
51. Pauleit D, Stoffels G, Bachofner A, Floeth FW, Sabel M, Herzog H et al. Comparison of (18) F-FET and (18) F-FDG PET in brain tumors. Nuclear Medicine and Biology 2009;36:779-87.
52. Plotkin M, Blechschmidt C, Auf G, Nyuyki F, Geworski L, Denecke T et al. Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas. Eur Radiol 2010;20:2496-502.
53. Pirotte BJ, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O et al. Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery 2009;64:471-81.
54. Piroth MD, Holy R, Pinkawa M, Stoffels G, Kaiser HJ, Galldiks N et al. Prognostic impact of postoperative, pre-irradiation (18) F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol 2011;99:218-24.
55. Grosu AL, Weber WA. PET for radiation treatment planning of brain tumours. Radiother Oncol 2010;96:325-7.
56. Matsuo M, Miwa K, Tanaka O, Shinoda J, Nishibori H, Tsuge Y et al. Impact of [11C]methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning. Int J Radiat Oncol Biol Phys 2012;82:83-9.
57. Grosu AL, Weber WA, Riedel E, Jeremic B, Nieder C, Franz M et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:64-74.
58. Levivier M, Massager N, Wikler D, Lorenzoni J, Ruiz S, Devriendt D et al. Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. J Nucl Med 2004;45:1146-54.
59. Weber DC, Zilli T, Buchegger F, Casanova N, Haller G, Rouzaud M et al. [(18) F]Fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma. Radiat Oncol 2008;3:44.
60. Piroth MD, Pinkawa M, Holy R, Klotz J, Schaar S, Stoffels G et al. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study. Strahlenfher Onkol 2012;188:334-9.
61. Lee IH, Piert M, Gomez-Hassan D, Junck L, Rogers L, Hayman J et al. Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2009;73:479-85.
62. Weber DC, Casanova N, Zilli T, Buchegger F, Rouzaud M, Nouet P et al. Recurrence pattern after [(18) F]fluoroethyltyrosinepositron emission tomography-guided radiotherapy for highgrade glioma: a prospective study. Radiotherapy and Oncology 2009;93:586-92.
63. Brandsma D, Van Den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 2009;22:633-8.
64. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-72.
65. Brandsma D, Stalpers L, Taal W, Sminia P, Van Den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9:453-61.
66. Shah AH, Snelling B, Bregy A, Patel PR, Tememe D, Bhatia R et al. Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality? J Neurooncol 2013;112:141-52.
67. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-72.
68. Ahluwalia MS, Wen PY. Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions. Expert Rev Anticancer Ther 2011;11:653-6.
69. Ullrich RT, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Me 2009;50:1962-8.
70. Crippa F, Alessi A, Serafini GL. PET with radiolabeled aminoacid. Q J Nucl Med Mol Imaging 2012;56:151-62.
71. Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T et al. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg 2003;98:1056-64.
72. Van Laere K, Ceyssens S, Van Calenbergh F, De Groot T, Menten J, Flamen P et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 2005;32:39-51.
73. Salber D, Stoffels G, Pauleit D, Oros-Peusquens AM, Shah NJ, Klauth P et al. Differential uptake of 0-(2-18F-fluoroefhyl)-L-tyrosine, L-3H-methionine, and 3H-deoxyglucose in brain abscesses. J Nucl Med 2007;48:2056-62.
74. Pöpperl G, Götz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004;31:1464-70.
75. Rachinger W, Goetz C, Pöpped G, Gildehaus FJ, Kreth FW, Holtmannspotter M et al. Positron emission tomography with 0-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 2005;57:505-11.
76. Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging 2014 [Epub ahead of print].
77. Popperl G, Kreth FW, Herms J, Koch W, Mehrkens JH, Gildehaus FJ et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med 2006;47:393-403.
78. Herrmann K, Czernin J, Cloughesy T, Bluemel C, Lai A, Pomykala K et al. Comparison of visual and semi-quantitative analysis of FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro Oncol 2014;16:603-9.
79. Karunanithi S, Sharma P, Kumar A, Khangembam BC, Bandopadhyaya GP, Kumar R et al. 18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2013;40:1025-35.
80. Galldiks N, Langen K, Holy R, Pinkawa M, Stoffels G, Nolte K et al. Assessment of treatment response in patients with glioblastoma using [18F]Fluoroethyl-L-Tyrosine PET in comparison to MRI. J Nucl Med 2012;53:1048-57.
81. Piroth MD, Pinkawa M, Holy R, Klotz J, Nussen S, Stoffels G et al. Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2011;80:176-84.
82. Galldiks N, Kracht LW, Burghaus L, Thomas A, Jacobs AH, Heiss WD et al. Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 2006;33:516-24.
83. Galldiks N, Kracht LW, Burghaus L, Ullrich RT, Backes H, Brunn A et al. Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Mol Imaging 2010;9:40-6.
84. Popped G, Goldbrunner R, Gildehaus FJ, Kreth FW, Tanner P, Holtmannspotter M et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 2005;32:1018-25.
85. Pöpped G, Götz C, Rachinger W, Schnell O, Gildehaus FJ, Tonn JC et al. Serial O-(2-[(18) F]fluoroethyl)-L:-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging 2006;33:792-800.
86. Galldiks N, Rapp M, Stoffels G, Fink GR, Shah NJ, Coenen HH et al. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging 2013;40:22-33.
87. Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H et al. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med 2011;52:856-64.
88. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T et al. Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy. Clin Cancer Res 2014;20:3550-9.
89. Cicone F, Minniti G, Romano A, Papa A, Scaringi C, Tavanti F et al. Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery. Eur J Nucl Med Mol Imaging 2015;42:103-11
90. Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 2008;49:694-9.
91. Galldiks N, Stoffels G, Filss CP, Piroth MD, Sabel M, Ruge MI et al. Role of O-(2-18F-Fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis. J Nucl Med 2012;53:1367-74.
92. Lizarraga KJ, Alien-Auerbach M, Czernin J, De Salles AA, Yong WH, Phelps ME et al. (18) F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. J Nucl Med 2014;55:30-6.
93. Pollack IF, Jakacki RI. Childhood brain tumors: epidemiology, current management and future directions. Nature Reviews Neurology 2011;7:495-506.
94. Galldiks N, Kracht LW, Berthold F, Miletic H, Klein JC, Herholz K et al. [11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors. J Neurooncol 2010;96:231-9.
95. Misch M, Guggemos A, Driever PH, Koch A, Grosse F, Steffen IG et al. F-FET-PET guided surgical biopsy and resection in children and adolescence with brain tumors. Childs Nerv Syst 2014 [Epub ahead of print]
96. Pirotte B, Goldman S, Van Bogaert P, David P, Wikler D, Rorive S et al. Integration of [11C]methionine-positron emission tomographic and magnetic resonance imaging for image-guided surgical resection of infiltrative low-grade brain tumors in children. Neurosurgery 2005;57:128-39.
97. Pirotte BJ, Lubansu A, Massager N, Wikler D, Van Bogaert P, Levivier M et al. Clinical impact of integrating positron emission tomography during surgery in 85 children with brain tumors. J Neurosurg Pediatr 2010;5:486-99.
98. Utriainen M, Metsahonkala L, Salmi TT, Utriainen T, Kalimo H, Pihko H et al. Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography. Cancer 2002;95:1376-86.
99. Heinzel A, Muller D, Langen KJ, Blaum M, Verburg FA, Mottaghy FM et al. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis. J Nucl Med 2013;54:1217-22.
100. Heinzel A, Stock S, Langen KJ, Müller D. Cost-effectiveness analysis of amino acid PET-guided surgery for supratentorial high-grade gliomas. J Nucl Med 2012;53:552-8.